CD38 and infection: Furthermore, increased risk of infection was also observed in a study exploring the effects of daratumumab in patients with systemic light-chain amyloidosis [94] and in clinical trials using isatuximab, a separate anti-CD38 monoclonal antibody, for multiple myeloma [95,96].